Conditions: Hepatic Impairment Healthy
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 22
Healthy volunteers: yes

Brief summary:
To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate Hepatic impairment compared to subjects with normal hepatic function

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: MCI-186
Intervention descriptions: intervention 1: 30 mg of edaravone will be administered intravenously over 60 minutes

Protocol document:
Prot_000.pdf: 







































































































































SAP_001.pdf: